Systemic Health Metrics Normative Values
Comprehensive reference of normal ranges for key systemic health metrics used in primary care and co-management. Many systemic conditions — including hypertension, diabetes, thyroid disease, and anaemia — manifest with characteristic ocular findings, making familiarity with these values essential for every optometrist.
1. Cardiovascular and Metabolic Metrics
Cardiovascular and metabolic disorders are among the leading systemic causes of vision-threatening ocular pathology, including hypertensive retinopathy, diabetic retinopathy, lipid deposits (arcus senilis, xanthelasma), and retinal vascular occlusions.
Blood Pressure (BP)
| Category | Systolic (mmHg) | Diastolic (mmHg) | Clinical Notes |
|---|---|---|---|
| Normal | <120 | <80 | Optimal cardiovascular risk profile |
| Elevated | 120–129 | <80 | Lifestyle modification recommended; monitor |
| Stage 1 Hypertension | 130–139 | 80–89 | Risk for AV nicking, arteriolar narrowing on fundus; co-manage with GP |
| Stage 2 Hypertension | ≥140 | ≥90 | Flame haemorrhages, cotton-wool spots, disc oedema possible; urgent referral if retinopathy present |
| Hypertensive Crisis | >180 | >120 | Hypertensive emergency — same-day referral; risk of ischaemic optic neuropathy, CRVO, CRAO |
Heart Rate (Resting Pulse)
| Parameter | Normal Range | Units | Clinical Notes |
|---|---|---|---|
| Resting Heart Rate (adult) | 60–100 | bpm | Well-conditioned athletes may be 40–60 bpm (normal for them) |
| Bradycardia | <60 | bpm | May indicate hypothyroidism, beta-blocker use, or cardiac conduction disease |
| Tachycardia | >100 | bpm | May indicate anaemia, hyperthyroidism, anxiety, infection, or dehydration |
Lipid Profile (Fasting)
| Parameter | Normal / Desirable Range | Units | Clinical Notes |
|---|---|---|---|
| Total Cholesterol — Desirable | <200 | mg/dL | Borderline high: 200–239; High: ≥240 |
| LDL Cholesterol — Optimal | <100 | mg/dL | Near-optimal: 100–129; Borderline high: 130–159; High: 160–189; Very high: ≥190. Arcus senilis at young age may indicate hypercholesterolaemia |
| HDL Cholesterol — Normal (M) | ≥40 | mg/dL | Low HDL (<40 M / <50 F) is an independent CVD risk factor; protective if ≥60 |
| HDL Cholesterol — Normal (F) | ≥50 | mg/dL | Cardiovascular protective level ≥60 mg/dL for all adults |
| Triglycerides — Normal | <150 | mg/dL | Borderline high: 150–199; High: 200–499; Very high: ≥500 (pancreatitis risk). Lipaemia retinalis (salmon-pink vessels) may be visible at very high levels |
Blood Glucose and HbA1c
| Parameter | Normal | Prediabetes | Diabetes | Units | Clinical Notes |
|---|---|---|---|---|---|
| Fasting Plasma Glucose | 70–99 | 100–125 | ≥126 | mg/dL | Confirmed by repeat testing; primary screening tool |
| 2-hr Post-OGTT Glucose | <140 | 140–199 | ≥200 | mg/dL | 75 g oral glucose tolerance test |
| Random Plasma Glucose | <140 | — | ≥200 + symptoms | mg/dL | Classic symptoms: polyuria, polydipsia, unexplained weight loss |
| HbA1c | <5.7% | 5.7–6.4% | ≥6.5% | % | Treatment target for diagnosed diabetics: <7.0% (ADA). Reflects average glucose over ~3 months. Diabetic retinopathy risk rises significantly above 7.0–8.0% |
Body Mass Index (BMI)
| Category | BMI Range | Units | Clinical Notes |
|---|---|---|---|
| Underweight | <18.5 | kg/m² | Nutritional deficiency risk; investigate if unexplained |
| Normal Weight | 18.5–24.9 | kg/m² | Associated with lowest mortality risk in most populations |
| Overweight | 25.0–29.9 | kg/m² | Increased risk of diabetes, hypertension, dyslipidaemia |
| Obesity Class I | 30.0–34.9 | kg/m² | Substantially elevated metabolic and cardiovascular risk |
| Obesity Class II | 35.0–39.9 | kg/m² | High risk; intervention typically recommended |
| Obesity Class III (Severe) | ≥40.0 | kg/m² | Very high risk; associated with idiopathic intracranial hypertension (papilloedema risk) |
Note: Lower BMI cut-offs apply for South and East Asian populations (overweight ≥23, obese ≥27.5 kg/m²) per WHO Asia-Pacific guidelines.
Waist Circumference
| Sex | Low Risk | Increased Risk | High Risk | Units | Clinical Notes |
|---|---|---|---|---|---|
| Male | <94 (<37 in) | 94–102 (37–40 in) | >102 (>40 in) | cm | Central adiposity is an independent CVD and metabolic disease risk factor |
| Female | <80 (<31.5 in) | 80–88 (31.5–34.6 in) | >88 (>34.6 in) | cm | Lower thresholds for Asian women: <80 cm (low risk) |
2. Blood and Organ Function Tests
Haematological and biochemical panels reveal systemic diseases with direct ocular manifestations. Anaemia can cause pale retinal vessels and flame haemorrhages; renal disease can drive hypertensive retinopathy; thyroid disease causes proptosis and lid retraction; iron deficiency is linked to optic disc swelling in some cases.
Complete Blood Count (CBC)
| Parameter | Normal Range (Adult) | Units | Clinical Notes |
|---|---|---|---|
| White Blood Cells (WBC) | 4.5–11.0 | × 10³/µL | Leukocytosis (>11) suggests infection/inflammation; leukaemia may cause retinal infiltrates |
| Red Blood Cells — Male | 4.7–6.1 | × 10⁶/µL | Polycythaemia vera can cause dilated tortuous retinal veins |
| Red Blood Cells — Female | 4.2–5.4 | × 10⁶/µL | Lower reference range in females due to hormonal differences |
| Haemoglobin — Male | 13.5–17.5 | g/dL | Anaemia (<13.5 M / <12.0 F) can cause pale disc, retinal haemorrhages, reduced contrast sensitivity |
| Haemoglobin — Female | 12.0–15.5 | g/dL | Pregnancy lowers reference range slightly; postmenopausal norms approach male values |
| Haematocrit — Male | 41–53% | % | Reflects proportion of blood volume occupied by RBCs |
| Haematocrit — Female | 36–46% | % | — |
| MCV (Mean Corpuscular Volume) | 80–100 | fL | Microcytic (<80): iron/thalassaemia; Macrocytic (>100): B12/folate deficiency (optic neuropathy risk) |
| Platelets | 150–400 | × 10³/µL | Thrombocytopenia (<150) can cause retinal haemorrhages; thrombocytosis (>400) increases clotting risk |
| Neutrophils (differential) | 50–70% | % of WBC | Absolute neutrophil count (ANC) <1.0 × 10³/µL = neutropenia; infection risk |
| Lymphocytes (differential) | 20–40% | % of WBC | Lymphocytosis in viral infections; lymphopenia may suggest immunosuppression |
| Monocytes (differential) | 2–8% | % of WBC | Monocytosis may indicate chronic inflammation or granulomatous disease (e.g., sarcoidosis) |
| Eosinophils (differential) | 1–4% | % of WBC | Elevated in allergic conditions, parasitic infections, and eosinophilic granulomatosis |
| Basophils (differential) | 0–1% | % of WBC | Basophilia rare; may indicate myeloproliferative disorders |
Kidney Function Tests (Renal Panel)
| Parameter | Normal Range (Adult) | Units | Clinical Notes |
|---|---|---|---|
| Serum Creatinine — Male | 0.74–1.35 | mg/dL | Elevated in reduced GFR; varies with muscle mass; less sensitive than eGFR alone |
| Serum Creatinine — Female | 0.59–1.04 | mg/dL | Lower in females due to lesser muscle mass |
| Blood Urea Nitrogen (BUN) | 7–20 | mg/dL | BUN:Cr ratio >20:1 suggests prerenal cause; <10:1 may suggest hepatic disease or low protein intake |
| eGFR (CKD-EPI) | ≥60 | mL/min/1.73m² | CKD stages: G1 ≥90 (normal), G2 60–89, G3a 45–59, G3b 30–44, G4 15–29, G5 <15 (kidney failure). Hypertensive retinopathy risk increases with worsening CKD |
| Sodium (Na⁺) | 136–145 | mEq/L | Hyponatraemia (<135) can cause cerebral oedema; hypernatraemia (>145) suggests dehydration |
| Potassium (K⁺) | 3.5–5.0 | mEq/L | Hypokalaemia (<3.5) and hyperkalaemia (>5.0) can cause cardiac arrhythmias |
| Chloride (Cl⁻) | 98–106 | mEq/L | Closely related to sodium; used to assess acid-base status |
| Bicarbonate (CO₂) | 22–29 | mEq/L | Reflects metabolic acid-base balance; low in metabolic acidosis |
| Calcium (Ca²⁺) — Total | 8.5–10.5 | mg/dL | Hypercalcaemia (sarcoidosis, hyperparathyroidism) can cause band keratopathy |
| Uric Acid — Male | 3.4–7.0 | mg/dL | Hyperuricaemia associated with gout; urate crystal deposition rare in ocular tissues |
| Uric Acid — Female | 2.4–6.0 | mg/dL | Rises after menopause; gout less common in females pre-menopausally |
Liver Function Tests (LFTs)
| Parameter | Normal Range (Adult) | Units | Clinical Notes |
|---|---|---|---|
| ALT (Alanine Aminotransferase) | 7–56 (M); 7–45 (F) | U/L | Most specific for hepatocellular injury; elevated in hepatitis, NAFLD |
| AST (Aspartate Aminotransferase) | 10–40 | U/L | Less specific than ALT; also raised in cardiac and muscle disease. AST:ALT >2 suggests alcoholic hepatitis |
| Alkaline Phosphatase (ALP) | 44–147 | U/L | Elevated in cholestasis, Paget's disease, bone metastases. Physiologically elevated in children/pregnancy |
| GGT (Gamma-Glutamyltransferase) — Male | 8–61 | U/L | Sensitive marker for alcohol use and cholestatic disease |
| GGT — Female | 5–36 | U/L | Lower reference range in females |
| Total Bilirubin | 0.2–1.2 | mg/dL | Jaundice visible when >2.5–3.0 mg/dL, including scleral icterus (yellow sclerae — an important ocular sign) |
| Direct (Conjugated) Bilirubin | 0–0.3 | mg/dL | Elevated in hepatocellular disease or biliary obstruction |
| Total Protein | 6.0–8.3 | g/dL | Low protein indicates malnutrition, malabsorption, or chronic liver/kidney disease |
| Albumin | 3.5–5.0 | g/dL | Marker of nutritional status and liver synthetic function; hypoalbuminaemia correlates with oedema |
Thyroid Function Tests
| Parameter | Normal Range (Adult) | Units | Clinical Notes |
|---|---|---|---|
| TSH (Thyroid-Stimulating Hormone) | 0.4–4.0 | mIU/L | First-line screening test. Low TSH = hyperthyroidism (Graves' disease: proptosis, lid retraction, lid lag, exposure keratopathy). High TSH = hypothyroidism (periorbital oedema, loss of lateral eyebrow) |
| Free T4 (Free Thyroxine) | 0.8–1.8 | ng/dL | Confirms hyper/hypothyroidism when TSH is abnormal; more reliable than total T4 |
| Free T3 (Free Triiodothyronine) | 2.3–4.1 | pg/mL | Active thyroid hormone; useful in T3 thyrotoxicosis (normal T4 with suppressed TSH) |
Iron Studies
| Parameter | Normal Range (Adult) | Units | Clinical Notes |
|---|---|---|---|
| Serum Iron — Male | 65–177 | µg/dL | Iron deficiency anaemia is the most common nutritional deficiency worldwide |
| Serum Iron — Female | 50–170 | µg/dL | Premenopausal women at higher risk due to menstrual losses |
| TIBC (Total Iron Binding Capacity) | 250–370 | µg/dL | Elevated TIBC in iron deficiency; decreased in chronic disease anaemia |
| Ferritin — Male | 12–300 | ng/mL | Most reliable measure of iron stores; <12 = depletion; also an acute-phase reactant (may be falsely elevated in inflammation) |
| Ferritin — Female | 12–150 | ng/mL | Postmenopausal values approach male range. Iron deficiency anaemia linked to optic disc oedema in rare cases |
| Transferrin Saturation | 20–50% | % | <20% suggests iron deficiency; >50% suggests iron overload (haemochromatosis) |
3. Respiratory and Other Key Indicators
Respiratory and urinary parameters, along with inflammation markers, provide additional context for systemic co-management. Chronic hypoxia and inflammatory states can affect retinal perfusion, accelerate diabetic and hypertensive retinopathy, and increase the risk of branch or central retinal vascular occlusions.
Oxygen Saturation (SpO₂)
| Category | SpO₂ Range | Units | Clinical Notes |
|---|---|---|---|
| Normal | 95–100 | % | Values ≥95% are acceptable in healthy adults at sea level |
| Mild Hypoxia | 91–94 | % | Monitor closely; supplemental O₂ may be warranted; assess for COPD, sleep apnoea |
| Moderate Hypoxia | 86–90 | % | Significant hypoxia; urgent medical assessment required |
| Severe Hypoxia | <86 | % | Emergency — chronic hypoxia can cause retinal haemorrhages and vascular dilation (e.g., high-altitude retinopathy analogue) |
Respiratory Rate
| Parameter | Normal Range | Units | Clinical Notes |
|---|---|---|---|
| Normal Adult (at rest) | 12–20 | breaths/min | Counted over 60 seconds; increases with exercise, fever, anxiety |
| Tachypnoea | >20 | breaths/min | Causes: pulmonary embolism, pneumonia, anxiety, metabolic acidosis, heart failure |
| Bradypnoea | <12 | breaths/min | Causes: opioid use, CNS depression, hypothyroidism; concerning if accompanied by low SpO₂ |
Urinalysis (Dipstick / Microscopy)
| Parameter | Normal Finding | Units | Clinical Notes |
|---|---|---|---|
| pH | 4.5–8.0 | — | Average ~6.0; alkaline urine suggests UTI (urea-splitting organisms) or metabolic alkalosis |
| Specific Gravity | 1.002–1.035 | — | Reflects concentration ability; fixed at 1.010 in CKD (isosthenuria) |
| Protein | Negative (<150 mg/day) | mg/day | Proteinuria signals renal disease; microalbuminuria (30–300 mg/g Cr) is an early diabetic nephropathy marker |
| Glucose | Negative | — | Glycosuria occurs when blood glucose exceeds renal threshold (~180 mg/dL); screen for diabetes |
| Ketones | Negative | — | Positive in DKA, starvation, low-carbohydrate diets |
| Blood / RBC | Negative (0–2 RBC/hpf) | RBC/hpf | ≥3 RBC/hpf = haematuria; investigate for malignancy, renal disease, trauma |
| WBC (Pyuria) | 0–5 WBC/hpf | WBC/hpf | >5 WBC/hpf suggests UTI; sterile pyuria may indicate interstitial nephritis or TB |
| Nitrite | Negative | — | Positive indicates nitrate-reducing bacteria (e.g., E. coli); high specificity for UTI |
| Leukocyte Esterase | Negative | — | Positive = pyuria; combined with nitrite strongly suggests bacterial UTI |
Inflammation Markers
| Parameter | Normal Range (Adult) | Units | Clinical Notes |
|---|---|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | <1.0 (low CVD risk) 1.0–3.0 (average risk) >3.0 (high CVD risk) | mg/L | General infection/inflammation: >10 mg/L. hs-CRP is a predictive CVD biomarker independent of LDL. Elevated in giant cell arteritis (GCA) — check urgently if suspected (risk of ischaemic optic neuropathy) |
| ESR (Erythrocyte Sedimentation Rate) — Male | <15 (or age ÷ 2) | mm/hr | Westergren method. In GCA (Horton's): typically >50 mm/hr, often >100. Normal ESR does not exclude GCA |
| ESR — Female | <20 (or [age + 10] ÷ 2) | mm/hr | Age-adjusted formula (Miller): females = (age + 10) ÷ 2; males = age ÷ 2 |
| Fibrinogen (Plasma) | 200–400 | mg/dL | Acute-phase reactant; elevated fibrinogen increases thrombosis risk — relevant to retinal vascular occlusion |
| Procalcitonin (PCT) | <0.10 | ng/mL | Unlikely bacterial infection if <0.25 ng/mL; antibiotic stewardship marker. 0.5–2.0 = possible bacterial infection; >2.0 = likely sepsis |
Clinical Disclaimer
These are general adult normative reference ranges compiled from reputable sources including the AHA, ADA, WHO, KDIGO, and published laboratory textbooks. Values may vary by laboratory, analyser, patient age, sex, ethnicity, and clinical context. Reference intervals are not absolute diagnostic thresholds. Always interpret results within the full clinical picture and in consultation with the referring physician or the reporting laboratory's own reference intervals.
References
1.Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13–e115. doi:10.1161/HYP.0000000000000065
2.American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1–S321. doi:10.2337/dc24-S001
3.National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106(25):3143–3421. doi:10.1161/circ.106.25.3143
4.World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva: WHO; 2000.
5.World Health Organization Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–163. doi:10.1016/S0140-6736(03)15268-3
6.World Health Organization. Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation. Geneva: WHO; 2008.
7.Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2024;114(4A):S1–S117. doi:10.1016/j.kint.2023.10.018
8.Burtis CA, Ashwood ER, Bruns DE, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 5th ed. Philadelphia: Elsevier Saunders; 2012.
9.Garber JR, Cobin RH, Gharib H, et al; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988–1028. doi:10.4158/EP12280.GL
10.Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363–369. doi:10.1161/01.CIR.0000053730.47739.3C
11.Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J (Clin Res Ed). 1983;286(6361):266. doi:10.1136/bmj.286.6361.266
12.Pagana KD, Pagana TJ, Pagana TN. Mosby's Manual of Diagnostic and Laboratory Tests. 6th ed. St. Louis: Elsevier; 2018.
13.World Health Organization. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Vitamin and Mineral Nutrition Information System. Geneva: WHO; 2011. (WHO/NMH/NHD/MNM/11.1).
14.Trinder J. Measurement of oxygen saturation. In: Bhatt DL, ed. Cardiovascular Intervention: A Companion to Braunwald's Heart Disease. Philadelphia: Elsevier; 2016:chap 5.
15.National Heart, Lung, and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (EPR-3). Bethesda: NIH/NHLBI; 2007. NIH Publication 08-4051.